Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · IEX Real-Time Price · USD
1.460
+0.080 (5.80%)
At close: Jul 23, 2024, 4:00 PM
1.440
-0.020 (-1.37%)
After-hours: Jul 23, 2024, 7:06 PM EDT

Company Description

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.

The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.

It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.

The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth.

It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide.

Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Akebia Therapeutics, Inc.
Akebia Therapeutics logo
Country United States
Founded 2007
IPO Date Mar 20, 2014
Industry Biotechnology
Sector Healthcare
Employees 167
CEO John P. Butler MBA

Contact Details

Address:
245 First Street
Cambridge, Massachusetts 02142
United States
Phone 617-871-2098
Website akebia.com

Stock Details

Ticker Symbol AKBA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001517022
CUSIP Number 00972D105
ISIN Number US00972D1054
Employer ID 20-8756903
SIC Code 2834

Key Executives

Name Position
John P. Butler MBA Chief Executive Officer, President, Interim Principal Financial Officer and Director
Michel Dahan Senior Vice President and Chief Operating Officer
Nicole R. Hadas J.D. Senior Vice President, Chief Legal Officer and Secretary
Dr. Steven Keith Burke M.D. Senior Vice President of Research and Development and Chief Medical Officer
Richard C. Malabre Chief Accounting Officer
Kimberly Garko Senior Vice President and Chief Technical Officer
Tracey Vetterick Vice President of Portfolio Strategy and Corporate Administration
Mercedes Carrasco Director of Corporate Communications
Meredith Bowman Senior Vice President and Chief People Officer
Carolyn Rucci Senior Vice President of Legal and General Counsel

Latest SEC Filings

Date Type Title
Jul 11, 2024 8-K Current Report
Jun 24, 2024 8-K Current Report
Jun 10, 2024 8-K Current Report
May 13, 2024 144 Filing
May 13, 2024 144 Filing
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
Apr 25, 2024 ARS Filing
Apr 25, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2024 DEF 14A Other definitive proxy statements